27 March 2019 1 Min Read
Novartis’s Mayzent approved to treat progressive multiple sclerosis
Mayzent, with a US list price of $88,500, is the first treatment approved for patients with secondary progressive MS in more than 15 years
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In